This is the case for primary and secondary KIT mutations which have been found in plasma from GIST patients [168,169] and for the extracellular domain of soluble KIT, which is a faithful biomarker of tumor outcome in patients treated with sunitinib after acquired imatinib resistance [170]. The gene discussed is KIT; the disease is neoplasm.